Share this video  

ASH 2022 | Updates on the Phase Ib KEYNOTE-013 trial: pembrolizumab in NHL

John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, briefly shares some updates from the Phase Ib KEYNOTE-013 trial (NCT01953692), which is evaluating the safety and efficacy of pembrolizumab in patients with Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Gilead: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria, Other: DSMB; Merck: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria; Medison Ventures: Consultancy; Antengene: Consultancy; Novartis: Honoraria; Janssen: Honoraria; Amgen: Honoraria; Astra Zeneca: Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding; Inctye: Honoraria; Seattle Genetics: Consultancy, Honoraria; Pfizer: Honoraria; Lymphoma Canada: Membership on an entity’s Board of Directors or advisory committees.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter